Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 18/20 | 0.54 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL27939383 | 0.83 | FDPS (0.65) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL9190293 | 0.82 | FDPS (0.56) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL28355003 | 0.74 | FDPS (0.47) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL12570894 | 0.74 | FDPS (0.56) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL29648124 | 0.73 | — | — | |
| SCHEMBL7032261 | 0.73 | FDPS (0.46) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL24616674 | 0.72 | FDPS (0.48) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL4663730 | 0.72 | FDPS (0.59) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL4093004 | 0.72 | FDPS (0.86) | FDPSGGPS1PDE3ALMNAADRB3 | |
| SCHEMBL14391031 | 0.72 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | FDPS 4229/4885GGPS1 3855/4885PDE3A 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.